Four months after it launched a clinical trial accelerator, Fresenius‘s (NYSE:FMS) renal research arm Frenova disclosed the initial participants.
Fourteen research centers around the U.S. will take part in the F1RST Up accelerator (Frenova Rapid Start Up). Frenova general manager said in prepared remarks that the participants include “some of the most productive clinical research sites in the world of renal research.”
The Waltham, Mass.-based accelerator is designed to propel more studies by taking administrative and contracting burdens out of the clinical trial setup process. Frenova launched F1RST Up in February. Frenova itself was relaunched in March 2014, after having been known as the Clinical Studies Group at FMCNA since its 2001 debut.
The 14 participants: Boise Kidney & Hypertension Institute, Meridian, ID; California Institute of Renal Research, San Diego, CAEastern Nephrology Associates, New Bern, NC; Gamma Medical Research, McAllen, TX; Knoxville Kidney Center, Knoxville, TN; Metro Hypertension & Kidney Center, St. Louis, MO; Nephrology & Hypertension Associates, Tupelo, MS; Nephrology Associates, Columbus, MS; Northeast Clinical Research Center, Bethlehem, PA; Paragon Health d/b/a Nephrology Center, Kalamazoo, MI; Renal Medicine Associates, Albuquerque, NM; South Carolina Nephrology and Hypertension Center, Orangeburg, SC; South Florida Research Institute, Lauderdale Lakes, FL; and Southwest Houston Research, Houston, TX.
In February, Frenova launched the renal research accelerator through an alliance of physician investigators in the nephrology research field.
The accelerator aims to boost study startup through the elimination of administrative and contracting burdens that plague clinical trials, and are often responsible for delays, the Waltham, Mass.-based company said.
